The Technical Analyst
Accelerate Diagnostics [AXDX]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Accelerate Diagnostics Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.04% $0.810
America/New_York / 19 apr 2024 @ 14:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17.55 mill |
| EPS: | -4.94 |
| P/E: | -0.160 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 21.66 mill |
| Avg Daily Volume: | 0.0974 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.160 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.160 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.734 - 0.936 ( +/- 12.09%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-17 | Phillips Jack | Buy | 59 928 | Common Stock |
| 2024-04-17 | Phillips Jack | Sell | 26 735 | Common Stock |
| 2024-04-17 | Phillips Jack | Sell | 59 928 | Employee Restricted Stock Units |
| 2024-04-12 | Phillips Jack | Buy | 59 928 | Common Stock |
| 2024-04-12 | Phillips Jack | Sell | 26 545 | Common Stock |
| INSIDER POWER |
|---|
| 96.82 |
| Last 100 transactions |
| Buy: 51 589 751 | Sell: 625 027 |
Forecast:
15:51 - $0.826
Live Trading Signals (every 1 min)
Forecast
1: 14:21 - $0.830
Forecast 2: 15:11 - $0.864
Forecast 3: 15:51 - $0.826
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.810 (5.04% ) |
| Volume | 0.0332 mill |
| Avg. Vol. | 0.0974 mill |
| % of Avg. Vol | 34.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AXDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Latest Press Releases
2024-03-28 16:05:00 - Press Release
Accelerate Diagnostics Reports Fourth Quarter And Full-year 2023 Financial Results
Tucson, ariz. , march 28, 2024 /prnewswire/ -- accelerate diagnostics, inc. (nasdaq: axdx) today announced financial results for the fourth quarter and year ended december 31, 2023.
2024-03-07 09:30:00 - Press Release
Accelerate Diagnostics Scheduled Call To Review 2023 Fourth Quarter And Full Year Results.
Tucson, ariz. , march 7, 2024 /prnewswire/ -- accelerate diagnostics, inc. (nasdaq: axdx) announced today that management will host a conference call on thursday, march 28, 2024, at 4:30 p.m.
2024-01-19 09:20:00 - Press Release
Accelerate Diagnostics Announces Pricing Of Approximately $15 Million Public Offering And Private Placement
Tucson, ariz. , jan. 19, 2024 /prnewswire/ -- accelerate diagnostics, inc. (nasdaq: axdx) (the "company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock.
2024-01-16 07:45:00 - Press Release
Accelerate Diagnostics Announces Launch Of Proposed Public Offering
Tucson, ariz. , jan. 16, 2024 /prnewswire/ -- accelerate diagnostics, inc. (nasdaq: axdx) (the "company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, pursuant to a registration statement on form s-1 filed with the u.s. securities and exchange commission (the "sec").
2024-01-07 20:00:00 - Press Release
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter And Full-year 2023 Results
Tucson, ariz. , jan. 7, 2024 /prnewswire/ -- accelerate diagnostics, inc. (nasdaq: axdx) (accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended december 31, 2023.
Latest News
2024-03-28 19:50:04 - Seeking Alpha
Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript
2024-03-28 18:46:06 - Zacks Investment Research
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.40 per share a year ago.
2023-11-29 09:46:11 - Zacks Investment Research
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
2023-11-22 11:18:48 - Zacks Investment Research
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-10-03 10:32:23 - Zacks Investment Research
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2023-08-10 19:01:46 - Zacks Investment Research
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $2.36 per share versus the Zacks Consensus Estimate of a loss of $1.50. This compares to loss of $2.40 per share a year ago.
2023-06-29 11:23:50 - Zacks Investment Research
Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?
Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
2023-05-23 10:53:28 - Zacks Investment Research
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
2023-05-11 22:36:10 - Seeking Alpha
Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Incorporated 2023 Q1 Results Conference Call. All participants will be in listen-only mode.
2023-05-11 19:02:48 - Zacks Investment Research
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.25 per share a year ago.